Author + information
- Received January 28, 2008
- Revision received March 18, 2008
- Accepted March 24, 2008
- Published online July 1, 2008.
- Nirat Beohar, MD, FACC⁎,⁎ (, )
- Ata K. Erdogan, MD⁎,
- Daniel C. Lee, MD⁎,
- Hani N. Sabbah, PhD, FACC†,
- Morton J. Kern, MD, FACC‡,
- John Teerlink, MD, FACC§,
- Robert O. Bonow, MD, FACC⁎ and
- Mihai Gheorghiade, MD, FACC⁎
- ↵⁎Reprint requests and correspondence:
Dr. Nirat Beohar, Bluhm Cardiovascular Institute, Feinberg School of Medicine, 8-790A Feinberg Pavilion, 251 East Huron Street, Northwestern Memorial Hospital, Chicago, Illinois 60611.
Acute heart failure syndromes (AHFS), with a high post-discharge mortality and rehospitalization rate, represent a significant public health burden. The treatment of patients hospitalized with AHFS often includes the use of vasoactive medications such as inotropes and vasodilators. Although such agents are frequently used, their safety and efficacy remain controversial. A significant number of patients with heart failure have underlying coronary artery disease and may be at greater risk from hemodynamic alterations that can diminish coronary perfusion. In AHFS, the relationship among vasoactive medications, coronary perfusion, and potential myocardial injury needs further investigation. Newer techniques now available to evaluate coronary perfusion should provide guidance for the evaluation of existing and future vasoactive therapies for AHFS.
- Received January 28, 2008.
- Revision received March 18, 2008.
- Accepted March 24, 2008.
- American College of Cardiology Foundation